What is Austedo?
Austedo (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT2) inhibitor FDA-approved for treating chorea associated with Huntington's disease and tardive dyskinesia in adults 1.
Formulation and Mechanism
Austedo contains deutetrabenazine, a hexahydro-dimethoxybenzoquinolizine derivative that works by inhibiting VMAT2, thereby reducing dopaminergic signaling that underlies involuntary movement disorders 1. The drug is available in two formulations:
- AUSTEDO XR (extended-release): 6,12,18,24,30,36,42, or 48 mg tablets using an osmotic delivery system
- AUSTEDO (immediate-release): 6,9, or 12 mg tablets 1
The molecular formula is C19H21D6NO3, with deuterium substitution that distinguishes it from tetrabenazine 1.
Important Clarification
You are asking about Austedo, NOT dextromethorphan/quinidine (Nuedexta)—these are completely different medications. The evidence provided about dextromethorphan/quinidine 2, 3, 4, 5, 6 is irrelevant to Austedo. Dextromethorphan/quinidine is approved for pseudobulbar affect, while Austedo treats movement disorders.
Clinical Use
Austedo is specifically indicated for:
- Chorea in Huntington's disease: Reduces involuntary choreiform movements
- Tardive dyskinesia: Treats drug-induced movement disorder typically caused by antipsychotic medications 1
The drug requires careful titration and monitoring, as VMAT2 inhibition can cause depression, parkinsonism, and other neuropsychiatric effects.